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Many questions in medical research are investigated 
in observational studies.1 Much of the research into 
the cause of diseases relies on cohort, case-control, or 
cross sectional studies. Observational studies also have 
a role in research into the benefits and harms of medi-
cal interventions.2 Randomised trials cannot answer 
all important questions about a given intervention. 
For example, observational studies are more suitable to 
detect rare or late adverse effects of treatments, and are 
more likely to provide an indication of what is achieved 
in daily medical practice.3
Research should be reported transparently so that 
readers can follow what was planned, what was done, 
what was found, and what conclusions were drawn.
The credibility of research depends on a critical assess-
ment by others of the strengths and weaknesses in study 
design, conduct, and analysis. Transparent reporting 
is also needed to judge whether and how results can 
be included in systematic reviews.4 5 However, in pub-
lished observational research important information is 
often missing or unclear. An analysis of epidemiologi-
cal studies published in general medical and specialist 
journals found that the rationale behind the choice of 
potential confounding variables was often not reported.6 
Only few reports of case-control studies in psychiatry 
explained the methods used to identify cases and 
controls.7 In a survey of longitudinal studies in stroke 
research, 17 of 49 articles (35%) did not specify the eli-
gibility criteria.8 Others have argued that without suffi-
cient clarity of reporting, the benefits of research might 
be achieved more slowly,9 and that there is a need for 
guidance on reporting observational studies.10 11
Recommendations on the reporting of research can 
improve reporting quality. The consolidated stand-
ards of reporting trials (CONSORT) statement was 
developed in 1996 and revised five years later.12 Many 
medical journals supported this initiative,13 which has 
helped to improve the quality of reports of randomised 
trials.14 15 Similar initiatives have followed for other 
research areas—for example, for the reporting of meta-
analyses of randomised trials16 or diagnostic studies.17 
We established a network of methodologists, research-
ers, and journal editors to develop recommendations 
for reporting observational research: the strengthening 
the reporting of observational studies in epidemiology 
(STROBE) statement.
Aims and use of STROBE statement
The STROBE statement is a checklist of items that 
should be addressed in articles reporting on the three 
main study designs of analytical epidemiology: cohort, 
case-control, and cross sectional studies. The intention 
is solely to provide guidance on how to report obser-
vational research well: these recommendations are not 
prescriptions for designing or conducting studies. Also, 
while clarity of reporting is a prerequisite to evalua-
tion, the checklist is not an instrument to evaluate the 
quality of observational research.
Here we present the STROBE statement and explain 
how it was developed. In a detailed companion article, 
the explanation and elaboration article,18-20 we justify 
the inclusion of the different checklist items and give 
methodological background and published examples 
of what we consider transparent reporting. We strongly 
recommend using the STROBE checklist in conjunc-
tion with the explanatory article, which is available 
freely on the websites of the publishing journals. 18-20
Development of STROBE statement
We established the STROBE Initiative in 2004, 
obtained funding for a workshop and set up a website 
(www.strobe-statement.org). We searched textbooks, 
bibliographic databases, reference lists, and personal 
files for relevant material, including previous recom-
mendations, empirical studies of reporting, and articles 
describing relevant methodological research. Because 
observational research makes use of many different 
study designs, we felt that the scope of STROBE had 
to be clearly defined early on. We decided to focus on 
the three study designs that are used most widely in 
analytical observational research: cohort, case-control, 
and cross sectional studies.
We organised a two day workshop in Bristol in 
September 2004. Twenty three people attended this 
meeting, including editorial staff from Annals of Internal 
Medicine, BMJ, Bulletin of the World Health Organization, 
International Journal of Epidemiology, JAMA, Preventive 
Medicine, and the Lancet as well as epidemiologists, 
methodologists, statisticians, and practitioners from 
Europe and North America. Written contributions were 
sought from 10 other people who declared an interest 
in contributing to STROBE but could not attend.
Three working groups identified items that were 
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StroBe statement—checklist of items that should be included in reports of observational studies 
Item No Recommendation
Title and abstract
	 1 (a)	Indicate	the	study’s	design	with	a	commonly	used	term	in	the	title	or	the	abstract
(b)	Provide	in	the	abstract	an	informative	and	balanced	summary	of	what	was	done	and	what	was	found
Introduction
Background/rationale 2 Explain	the	scientific	background	and	rationale	for	the	investigation	being	reported
Objectives 3 State	specific	objectives,	including	any	prespecified	hypotheses
Methods
Study	design 4 Present	key	elements	of	study	design	early	in	the	paper
Setting 5 Describe	the	setting,	locations,	and	relevant	dates,	including	periods	of	recruitment,	exposure,	follow-up,	and	data	collection
Participants 6 (a)	Cohort study�Give	the	eligibility	criteria,	and	the	sources	and	methods	of	selection	of	participants.	Describe	methods	of	follow-up
Case-control study�Give	the	eligibility	criteria,	and	the	sources	and	methods	of	case	ascertainment	and	control	selection.	Give	the	
rationale	for	the	choice	of	cases	and	controls
Cross sectional study�Give	the	eligibility	criteria,	and	the	sources	and	methods	of	selection	of	participants
(b) Cohort study�For	matched	studies,	give	matching	criteria	and	number	of	exposed	and	unexposed
Case-control study�For	matched	studies,	give	matching	criteria	and	the	number	of	controls	per	case
Variables 7 Clearly	define	all	outcomes,	exposures,	predictors,	potential	confounders,	and	effect	modifiers.	Give	diagnostic	criteria,	if	applicable
Data	sources/	measurement 8* 	For	each	variable	of	interest,	give	sources	of	data	and	details	of	methods	of	assessment	(measurement).	Describe	comparability	of	
assessment	methods	if	there	is	more	than	one	group
Bias 9 Describe	any	efforts	to	address	potential	sources	of	bias
Study	size 10 Explain	how	the	study	size	was	arrived	at
Quantitative	variables 11 Explain	how	quantitative	variables	were	handled	in	the	analyses.	If	applicable,	describe	which	groupings	were	chosen	and	why
Statistical	methods 12 (a)	Describe	all	statistical	methods,	including	those	used	to	control	for	confounding
(b)	Describe	any	methods	used	to	examine	subgroups	and	interactions
(c)	Explain	how	missing	data	were	addressed
(d) Cohort study�If	applicable,	explain	how	loss	to	follow-up	was	addressed
Case-control study�If	applicable,	explain	how	matching	of	cases	and	controls	was	addressed
Cross sectional study�If	applicable,	describe	analytical	methods	taking	account	of	sampling	strategy
(e)	Describe	any	sensitivity	analyses
Results
Participants 13* (a)	Report	numbers	of	individuals	at	each	stage	of	study�eg	numbers	potentially	eligible,	examined	for	eligibility,	confirmed	
eligible,	included	in	the	study,	completing	follow-up,	and	analysed
(b)	Give	reasons	for	non-participation	at	each	stage
(c)	Consider	use	of	a	flow	diagram
Descriptive	data 14* (a)	Give	characteristics	of	study	participants	(eg	demographic,	clinical,	social)	and	information	on	exposures	and	potential	confounders
(b)	Indicate	number	of	participants	with	missing	data	for	each	variable	of	interest
(c)	Cohort study�Summarise	follow-up	time	(eg	average	and	total	amount)
Outcome	data 15* Cohort study�Report	numbers	of	outcome	events	or	summary	measures	over	time
Case-control study�Report	numbers	in	each	exposure	category,	or	summary	measures	of	exposure
Cross sectional study�Report	numbers	of	outcome	events	or	summary	measures
Main	results 16 (a)	Report	the	numbers	of	individuals	at	each	stage	of	the	study�eg	numbers	potentially	eligible,	examined	for	eligibility,	confirmed	
eligible,	included	in	the	study,	completing	follow-up,	and	analysed
(b)	Give	reasons	for	non-participation	at	each	stage
(c)	Consider	use	of	a	flow	diagram
Other	analyses 17 Report	other	analyses	done�eg	analyses	of	subgroups	and	interactions,	and	sensitivity	analyses
Discussion
Key	results 18 Summarise	key	results	with	reference	to	study	objectives
Limitations 19 Discuss	limitations	of	the	study,	taking	into	account	sources	of	potential	bias	or	imprecision.	Discuss	both	direction	and	magnitude	
of	any	potential	bias
Interpretation 20 Give	a	cautious	overall	interpretation	of	results	considering	objectives,	limitations,	multiplicity	of	analyses,	results	from	similar	
studies,	and	other	relevant	evidence
Generalisability 21 Discuss	the	generalisability	(external	validity)	of	the	study	results
Other information
Funding 22 Give	the	source	of	funding	and	the	role	of	the	funders	for	the	present	study	and,	if	applicable,	for	the	original	study	on	which	the	
present	article	is	based
*Give	information	separately	for	cases	and	controls	in	case-control	studies	and,	if	applicable,	for	exposed	and	unexposed	groups	in	cohort	and	cross	sectional	studies.
The	STROBE	checklist	is	best	used	in	conjunction	with	the	explanation	and	elaboration	article.18-20	This	article	and	separate	versions	of	the	checklist	for	cohort,	case-control,	and	cross	sectional	
studies	are	available	at	www.strobe-statement.org.
deemed to be important to include in checklists for each 
type of study. A provisional list of items prepared in 
advance (available from our website) was used to facil-
itate discussions. The three draft checklists were then 
discussed by all participants and, where possible, items 
were revised to make them applicable to all three study 
designs. In a final plenary session, the group decided 
on the strategy for finalising and disseminating the 
STROBE statement.
After the workshop we drafted a combined checklist 
including all three designs and made it available on our 
website. We invited participants and additional scientists 
ANALYSIS
808	 	 	 BMJ | 20 octoBer 2007 | VoluMe 335
and editors to comment on this draft checklist. We sub-
sequently published three revisions.
STROBE components
The STROBE statement is a checklist of 22 items that 
we consider essential for good reporting of observa-
tional studies (table). These items relate to the article’s 
title and abstract (item 1), the introduction (items 2 and 
3), methods (items 4-12), results (items 13-17), discus-
sion sections (items 18-21), and other information (item 
22 on funding). Eighteen items are common to all three 
designs, while four (items 6, 12, 14, and 15) are design 
specific, with different versions for all or part of the 
item. For some items (indicated by asterisks), informa-
tion should be given separately for cases and controls in 
case-control studies, or exposed and unexposed groups 
in cohort and cross sectional studies. Although the table 
is a single checklist, the STROBE website provides sep-
arate checklists for each of the three study designs.
Implications and limitations
The STROBE statement was developed to assist 
authors when writing up analytical observational stud-
ies, to support editors and reviewers when considering 
such articles for publication, and to help readers when 
critically appraising published articles.
Observational studies serve a wide range of pur-
poses, on a continuum from the discovery of new 
findings to the confirmation or refutation of previous 
findings.18-20 Some studies are essentially exploratory 
and raise interesting hypotheses. Others pursue clearly 
defined hypotheses in available data. In yet another 
type of studies, the collection of new data is planned 
carefully on the basis of an existing hypothesis. We 
believe the present checklist can be useful for all these 
studies, since the readers always need to know what 
was planned (and what was not), what was done, what 
was found, and what the results mean. 
We acknowledge that STROBE is currently lim-
ited to three main observational study designs. We 
would welcome extensions that adapt the checklist 
to other designs—for example, case crossover stud-
ies or ecological studies—and also to specific topics. 
Four extensions are now available for the CONSORT 
statement.21-24 A first extension to STROBE is under 
way for gene-disease association studies: the STROBE 
Extension to Genetic Association studies (STREGA) 
initiative.25 We ask those who aim to develop exten-
sions of the STROBE statement to contact the coordi-
nating group first to avoid duplication of effort.
The STROBE statement should not be interpreted 
as an attempt to prescribe the reporting of observa-
tional research in a rigid format. The checklist items 
should be addressed in sufficient detail and with clar-
ity somewhere in an article, but the order and for-
mat for presenting information depends on author 
preferences, journal style, and the traditions of the 
research field. For instance, we discuss the reporting 
of results under a number of separate items, while 
recognising that authors might address several items 
within a single section of text or in a table. Also, item 
22, on the source of funding and the role of funders, 
could be addressed in an appendix or in the methods 
section of the article. We do not aim at standardising 
reporting. Authors of randomised clinical trials were 
asked by an editor of a specialist medical journal to 
“CONSORT” their manuscripts on submission.26 We 
believe that manuscripts should not be “STROBEd,” 
in the sense of regulating style or terminology. We 
encourage authors to use narrative elements, including 
the description of illustrative cases, to complement the 
essential information about their study, and to make 
their articles an interesting read.27
We emphasise that the STROBE statement was not 
developed as a tool for assessing the quality of published 
observational research. Such instruments have been 
developed by other groups and were the subject of a 
recent systematic review.28 In the explanatory article 
we used several examples of good reporting from 
studies whose results were not confirmed in further 
research; the important feature was the good report-
ing, not the quality of the research. However, if authors 
and journals adopt the STROBE statement, issues such 
as confounding, bias, and generalisability could become 
more transparent, which might help temper the over-
enthusiastic reporting of new findings in the scientific 
 community and popular media,29 and improve the 
 methods of studies in the long term. Better reporting may 
also help to have more informed decisions about when 
new studies are needed, and what they should address.
We did not undertake a comprehensive system-
atic review for each of the checklist items and sub-
items, or do our own research to fill gaps in the 
evidence base. Furthermore, although no one was 
excluded from the process, the composition of the 
group of contributors was influenced by existing 
networks and was not representative in terms of 
geography and probably was not representative 
in terms of research interests and disciplines. We 
stress that STROBE and other recommendations on 
the reporting of research should be seen as evolv-
ing documents that require continual assessment, 
refinement, and, if necessary, change. We wel- 
come suggestions for the further dissemination of 
STROBE—for example, by republishing this article 
in specialist journals and in journals published in 
other languages. Groups or individuals who intend 
to translate the checklist to other languages should 
consult the coordinating group beforehand. We will 
revise the checklist in the future, taking into account 
comments, criticism, new evidence, and experience 
from its use. We invite readers to submit their com-
ments through the STROBE website.
to encourage dissemination of the stRoBE statement, this article is free 
on bmj.com and is also published and freely available in annals of Internal 
Medicine, Bulletin of the World health organization, Epidemiology, the 
Lancet, PLos Medicine, and Preventive Medicine. For details on further 
use, see stRoBE website (www.strobe-statement.org).
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